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The dose can make the poison: lessons learned
from adverse in vivo toxicities caused by RNAi
overexpression
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Abstract
For the past five years, evidence has accumulated that vector-mediated robust RNA interference (RNAi) expression
can trigger severe side effects in small and large animals, from cytotoxicity and accelerated tumorigenesis to organ
failure and death. The recurring notions in these studies that a critical parameter is the strength of RNAi expression
and that Exportin-5 and the Argonaute proteins are rate-limiting mammalian RNAi, strongly imply dose-dependent
saturation of the endogenous miRNA pathway as one of the underlying mechanisms. This minireview summarizes
the relevant work and data leading to this intriguing model and highlights potential avenues by which to alleviate
RNAi-induced toxicities in future clinical applications.
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Background
Since the seminal 1998 report of RNA interference
(RNAi) in nematodes [1], the ascent of RNAi technolo-
gies from a curious phenomenon in worms to a widely
and routinely used surrogate genetic tool in higher
eukaryotes, as well as one of our most promising thera-
peutic modalities, has been nothing short of meteoric.
Ironically, though, in the same year, 2006, that the rise
of RNAi temporarily culminated in the Nobel Prize for
its pioneers Andrew Fire and Craig Mello, Mark Kay’s
group published a startling study reporting fatal side
e f f e c t sf r o ma b u n d a n tR N A ie x p r e s s i o ni nt h el i v e r so f
adult mice [2]. Since then a series of further studies in
various species and tissues have solidified the original
idea that one crucial mechanism underlying the
observed in vivo toxicities or fatalities is adverse satura-
tion of the endogenous miRNA machinery by ectopic
RNAi triggers. Herein I briefly review these papers and
findings before highlighting key lessons that we can
learn and new avenues that we can now take.
From observations of dose-dependent in vivo RNAi
toxicities…
The 2006 Grimm et al. study [2] came as a surprise to
the field, as the wealth of previous reports had proved
RNAi’s superior efficacy and thus fostered a rapid trans-
lation of RNAi technologies from bench to bedside.
What was so different in this particular work was the
unique combination of (1) an utmost potent viral RNAi
delivery vector (self-complementary adeno-associated
virus serotype 8 (scAAV8)), (2) a powerful promoter
(U6, one of the strongest known RNA polymerase III
promoters) driving small hairpin RNA (shRNA) expres-
sion and (3) delivery of high vector doses (directly into
the hepatic circulation in some animals) [2]. This
experimental setup not only ensured complete liver
transduction in the injected mice but also introduced,
on average, thousand RNAi expression templates into
each hepatocyte, likely resulting in the transcription of
hundreds of thousands of shRNA molecules per cell.
Unsurprisingly, at least in retrospect, such massive
overloading of the cells with exogenous RNAi inducers
was most likely more than what their endogenous RNAi
machinery could handle. This is evidenced by the
study’s finding that more than 20 different abundantly
expressed shRNAs caused substantial hepatotoxicities
and eventual fatalities, regardless of the presence or
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reactions, such as immune responses. Notably, shRNA
overexpression and toxicity correlated with dysregula-
tion of hepatocellular miRNAs, implying competition of
shRNAs and miRNAs for rate-limiting factors and sub-
stantiating the idea that saturation of the liver RNAi
machinery was a major cause of toxicity.
Subsequently, a series of other studies made very simi-
lar observations in mouse livers and came to a compar-
able conclusion. This includes a recent report by Borel
and colleagues [3], who also used scAAV8 for in vivo
shRNA transduction and noted viral dose-dependent
hepatotoxicities in mice, which were evidenced by
increases in plasma transaminases and animal weight
loss and culminated in one death. Furthermore, they
also observed shRNA-dependent downregulation of
three cellular miRNAs, including liver-specific miR-122,
corroborating that shRNA overexpression can adversely
perturb the miRNA/RNAi machinery in vivo.I nl i n e
with this evidence, Ahn et al. [4] noted gradual hepato-
cyte death in mice treated with shRNA-expressing gut-
less adenoviral vectors that correlated with the buildup
of mature shRNA molecules and the upregulation of
miRNA-controlled hepatic genes.
Researchers who have studied organs other than the
liver have described similar notions of shRNA-associated
toxicities in the central nervous system (CNS) of the
mouse and rat. Notable examples came from Beverly
Davidson’s group [5], who expressed three shRNAs plus
a control against the Huntington’sd i s e a s eh o m o l o gi n
mouse striatum and observed significant neurotoxicities
with two active shRNAs as well as the control shRNA.
All shRNAs were expressed from the potent U6 promo-
ter and were delivered via efficient AAV1 vectors, and
toxicity correlated with shRNA abundance but not with
silencing activity. In a later study, the same group again
noted severe neurotoxicity with another AAV/U6-driven
shRNA, this time in mouse cerebellum [6]. These condi-
tions and findings are highly reminiscent of those in the
Grimm et al. study in the liver [2], implying that non-
specific shRNA toxicity can occur in multiple cell and
tissue types in vivo.I n d e e d ,M a r t i net al. [7] recently
inadvertently recapitulated shRNA-induced lethalities
using AAV1/U6 vectors to express three distinct
shRNAs in the striata of various mouse strains and vali-
dated the evidence for the involvement of shRNA-
induced miRNA dysregulation.
Exemplifying that shRNA toxicity in the CNS is not
species-specific, Ulusoy et al. [8] reported cytotoxicity
from shRNA overexpression in the rat substantia nigra.
Using AAV5 to deliver two shRNAs against tyrosine
hydroxylase plus two controls, that group noted a dose-
dependent loss of nigral dopaminergic neurons with all
four shRNAs. Similarly, Khodr and co-workers [9]
reported neuron loss in the substantia nigra of rats
injected with AAV2 expressing an shRNA against a-
synuclein or an irrelevant control shRNA. Moreover,
Ehlert et al. [10] found a dose-dependent adverse tissue
response and neuronal degeneration following AAV1-
mediated expression of three distinct shRNAs (including
one control) in the red nucleus of rats. Lowering virus
amounts, and thus shRNA expression, reduced these
effects, and toxicity was absent when an inferior (as
compared to AAV1) AAV5 vector was used in another
cell type, together providing further support for the
saturation model.
Next to rodent liver and CNS, Bish et al. [11] recently
reported severe cardiac dysfunction and toxicity in three
dogs treated with scAAV6-expressing anti-phospholam-
ban shRNA. Their finding that shRNA treatment is
associated with alterations in expression of two cellular
miRNAs suggests that toxic oversaturation of endogen-
ous RNAi pathways can also occur in large animals.
…to first insights into the underlying cellular
mechanisms…
As noted, the recurrent correlations of cytotoxicities
with shRNA abundance and miRNA dysregulation in
many reports fuel the model that ectopic shRNA expres-
sion can saturate key factors in the miRNA processing
pathway. Ample support for this concept is actually pro-
vided by numerous studies recapitulating the in vivo
findings in cultured cells. For instance, the Chen group
[12] showed that high-level, U6-driven shRNA expres-
sion from a lentiviral vector causes cytotoxicity in pri-
mary human lymphocytes, which could be relieved by
encoding the same shRNA under the weaker H1 promo-
ter. Likewise, Pan et al. [13] noted downregulation of
hepatic miRNAs in a liver cell line infected with U6-
shRNA-encoding lentiviral vectors. Moreover, Khan et
al. [14] conducted an extensive meta-analysis of over
150 siRNA or shRNA transfection experiments in which
they described frequent upregulation of miRNA-con-
trolled genes upon abundant siRNA and/or shRNA
expression. Importantly, some of these studies also pro-
vide clues to the limiting RNAi factors. Thus far the
leading suspects that have emerged from this in vitro
work are Exportin-5, the nuclear karyopherin that shut-
tles shRNAs and miRNAs into the cytoplasm, as well as
Argonaute-2, a critical RNA-induced silencing complex
(RISC) component that binds and cleaves targeted
mRNAs [2,15-18]. Interestingly, Bennasser and collea-
gues [19] recently reported that Exportin-5 saturation
may also reduce Dicer expression and hence activity,
adding another layer of complexity to the cellular
mechanisms underlying RNAi toxicity.
Validating the potential rate-limiting nature of these
factors in an in vivo setting is obviously more
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In fact, hepatic Exportin-5 and Argonaute-2 coexpres-
sion from AAV vectors was recently shown to increase
shRNA potency in the livers of adult mice and to partly
alleviate RNAi toxicity, implying that these two factors
are also prone to exogenous saturation in vivo [2,17].
There is further indirect support in a recent study [7]
for a correlation of diminished Exportin-5 levels in a
particular mouse strain with an increased susceptibility
to shRNA-induced neurotoxicity, and others have pro-
posed that the relatively low Exportin-5 expression in
the brain may generally render this organ particularly
sensitive to adverse saturation effects [10]. Notably,
despite the absence of reports to date on in vivo mor-
bidities or deaths resulting from siRNA delivery, there is
clear evidence that high intracellular siRNA abundance
can also saturate critical RNAi components. For
instance, the Rossi group [15] reported that transfected
siRNAs can compete with each other, with cotransfected
shRNAs or with endogenous miRNAs for RISC incor-
poration. As with shRNAs, Argonaute-2 appears to play
a crucial role in this process, as its overexpression has
been shown to at least partially relieve some of these
competition effects [17]. Moreover, as noted above,
Khan et al. [14] found that siRNA transfection fre-
quently perturbs cellular miRNA expression and thus
regulation of endogenous gene expression. These and
additional similar findings clearly imply that dose- and
saturation-dependent cytotoxicity is not restricted to
vector-encoded shRNAs, but can be induced and
observed with siRNA delivery. That more severe effects
still have not been noted in vivo m a yb er e l a t e dt ot h e
facts that (1) achieving high intracellular doses of siR-
NAs is difficult compared to shRNA expression and (2)
the typically short-term kinetics of siRNA persistence
and activity may not suffice to perturb the cellular RNAi
machinery to an extent that would cause toxicity.
...and to novel clinically relevant strategies to alleviate
RNAi toxicity
The available evidence to date suggests that a major
goal for future clinical RNAi applications must be to
thwart the risk of saturating endogenous RNAi path-
ways by exogenous shRNAs without compromising
their therapeutic efficacy. Toward this aim, a multitude
of concepts can be envisioned that fall roughly into two
categories: improvements in the RNAi vector itself or
advances in our understanding of cellular RNAi
mechanisms (Figure 1).
The first category comprises various practical strate-
gies that can be adopted to limit intracellular steady-
state levels of ectopic RNAi substrates to tolerable yet
still effective degrees. Accordingly, one approach is the
use of weaker shRNA promoters, such as H1 or 7SK
instead of U6, or moderate and/or tissue-specific RNA
polymerase II promoters [17,20]. Lowering vector doses
or switching to a less potent viral variant can likewise
reduce shRNA expression to safer levels, especially since
the therapeutic window for shRNA expression appears
to be relatively wide (at least for potent molecules), fre-
quently allowing variations in vector doses of more than
two orders of magnitude without major losses in target
knockdown activities [2,8,10,17]. However, for some
applications, lowering the vector doses below a critical
threshold may adversely interfere with a need for com-
plete target tissue transduction, implying that this ave-
nue will have to be adapted to each scenario [6,10].
Another useful strategy may be to express active RNAi
sequences from a miRNA scaffold, which has proved
particularly valuable in the CNS thus far [5,6]. The rea-
sons for the presumably lower in vivo toxicity from
miRNA-like vectors as compared to shRNA counter-
parts are still not fully clear, but the generally reduced
abundance of mature miRNA strands may play a critical
role. Also, since miRNAs are being shunted through an
endogenous processing pathway, their entry into RISC
m i g h tb es l o w e rc o m p a r e dt oh i g h l ye x p r e s s e ds h R N A s
or transfected siRNAs. It has been proposed that this
may in turn further reduce the likelihood of adverse
saturation effects [15]. On the other hand, since miRNA
biogenesis already begins with Drosha processing (a step
that is skipped by siRNAs and shRNAs), an important
question for future research will be to investigate the
possibility of specific nuclear saturation events with
miRNA vectors. Combining low-copy RNAi strategies
with other modes of gene silencing, such as U1 inhibi-
tion or ribozymes, can also maintain high efficiency
while minimizing saturation risks [21-23].
Regarding the second category, several laboratories
have initiated attempts to mathematically model RNAi
in mammalian cells [24,25], which will hopefully further
help researchers to rationally improve the efficacy and
safety of their RNAi strategies. For instance, Cuccato et
al. [24] calculated the number of active RISC to be in a
range from 10
3 to 10
4 in a typical mammalian cell and
accordingly proposed that the number of ectopic RNAi
triggers ideally be kept below this range to avoid satura-
tion effects. Likewise, Arvey et al. [25] presented a
mathematical model according to which the efficiency
of therapeutic RNAi molecules on their intended target
depends on the overall abundance of potential binding
sites in the cell. Hence an important implication is that
to prevent this dilution effect and to maximize siRNA
or shRNA potency, sequences that have minimal off-tar-
gets should be preferred. This will not only eliminate
unintended silencing effects but also permit decreasing
the dose of the RNAi trigger, which will in turn mini-
mize the risk of nonspecific saturation effects.
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screening libraries of RNAi inducers in a high-through-
put fashion for potent and safe molecules [26]. As with
the modeling approach, their aim is to identify favorable
features of RNAi triggers and unravel rate-limiting cellu-
lar steps and components to ultimately deduce guide-
lines for the rational design of optimized RNAi
templates and strategies. Most critical here will be the
1 2 3 4 5
1 2 3
Figure 1 Schematic overview of strategies to alleviate in vivo RNAi toxicity. As explained in the text, one can roughly distinguish strategies that aim
to improve the RNA interference (RNAi) vector itself (top half) or that instead focus on the cellular component (bottom half). Amongst the former, the
main approaches reported so far include a reduction of short hairpin RNA (shRNA) expression per given vector dose via the use of moderate promoters (1-
red), a limitation of the overall vector dose applied (2-red), shRNA delivery via a specific viral vector serotype (3-red), embedding of the shRNA sequence
into a miRNA scaffold (4-red) or a combination of RNAi technologies with further inhibitors of gene expression (5-red). On the cellular side, currently
pursued strategies comprise mathematical modeling of all rate-limiting factors in the cell (1-purple), cell-bas e ds c r e e n i n gf o rp o t e n ta n dm i n i m a lly toxic
RNAi triggers (2-purple) and controlled overexpression of known rate-limiting cellular components, together with the RNAi vector (3-purple).
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sideration that the manifestation and extent of RNAi-
associated toxicities can vary greatly with the specific
cell type and depend on many other variables that may
not be easy to truly mimic in vitro.A ne x a m p l eo ft h e
latter is the observation by Beer et al. [27] that even low
doses of vector-encoded shRNAs can have fatal side
e f f e c t si nm i c et h a tc o e x p r e s sap r o t o - o n c o g e n ei nt h e
liver. In these animals, even marginal hepatocyte death
was sufficient to accelerate tumorigenesis, a phenom-
enon that would have been missed in isolated cell cul-
tures. If, however, such cultures have to be used, it may
be important to employ primary human cells (where
available) instead of established cell lines. This is implied
by the study by An et al. [12], for instance, wherein
shRNA cytotoxicity manifested only in primary lympho-
cytes and not in a human T-cell line. Also notable along
t h e s el i n e sa r ed a t ap u b l i s h e db yM a r t i net al. [7] indi-
cating that the genetic background of rodents can mod-
ify their sensitivity to RNAi toxicity, together suggesting
that selecting proper cell types and animal strains is a
very important consideration in preclinical RNAi trials.
The aforementioned strategy to deliberately coexpress
known rate-limiting cellular RNAi factors can boost
shRNA potency and reduce toxicity [2,17], yet the long-
term outcomes of this particular approach for the cell and
organism remain to be studied. It is interesting to note in
this context that a series of recent findings have indicated
that essential parts of the RNAi machinery are inherently
dysregulated in many cancers or during infections with
viral pathogens [28]. This suggests that, along with the
mathematical strategies described above, an important goal
for future (pre-)clinical research should be quantitative deli-
neation of the exact concentrations of all RNAi compo-
nents in a given cell, of the intrinsic and extrinsic silencing
triggers and of their target mRNAs so that researchers can
become able to adapt and fine-tune therapeutic strategies
toward maximum efficiency and minimum toxicity.
Conclusion
Regarding the pace at which the field has moved from
the first notion of in vivo RNAi toxicities in 2006 to
today’s wealth of novel options and innovative concepts
to alleviate these toxicities, and considering the rapidly
increasing numbers of studies reporting the successful
implementation of these avenues in animals, we can cer-
tainly stay highly optimistic that the realization of safe
and potent RNAi strategies in humans remains a most
realistic goal for the near future.
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